Document is current
Any future updates will be listed below
-
Authors
Walesky, Chad M. https://orcid.org/0000-0003-3800-3453
Kolb, Kellie E. https://orcid.org/0000-0001-8840-7363
Winston, Carolyn L. https://orcid.org/0000-0003-0140-2426
Henderson, Jake https://orcid.org/0000-0003-1981-359X
Kruft, Benjamin https://orcid.org/0000-0001-5964-0836
Fleming, Ira https://orcid.org/0000-0002-4691-6933
Ko, Sungjin https://orcid.org/0000-0002-6079-5939
Monga, Satdarshan P. https://orcid.org/0000-0002-8437-3378
Mueller, Florian https://orcid.org/0000-0002-9622-4396
Apte, Udayan https://orcid.org/0000-0002-6741-7164
Shalek, Alex K. https://orcid.org/0000-0001-5670-8778
Goessling, Wolfram https://orcid.org/0000-0001-9972-1569
- License Information
-
More Information
Article History
Received: 3 October 2019
Accepted: 12 October 2020
First Online: 19 November 2020
Competing interests
: W.G. is a consultant for Camp4 Therapeutics. A.K.S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Cogen Therapeutics, Ochre Bio, and Dahlia Biosciences. S.P.M has an advisory board role for Surrozen. C.M.W., K.E.K., C.L.W., J.H., B.K., I.F., F.M., S.K., and U.A. have no competing interests to declare.
